About Acer Therapeutics
Acer Therapeutics is a company based in Cambridge (United States) founded in 1991 by Chris Schelling was acquired by Zevra in November 2023.. The company has 37 employees as of December 31, 2022. Acer Therapeutics has completed 1 acquisition, including Opexa Therapeutics. Acer Therapeutics offers products and services including OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities. Acer Therapeutics operates in a competitive market with competitors including Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Cambridge, United States
- Employees 37 as on 31 Dec, 2022
- Founders Chris Schelling
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Acer Therapeutics
Acer Therapeutics offers a comprehensive portfolio of products and services, including OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for Maple Syrup Urine Disease conditions
Investigational treatment for Vascular Ehlers-Danlos Syndrome
Explores new therapies for ultra-rare diseases
Unlock access to complete
Funding Insights of Acer Therapeutics
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $1.5M
-
First Round
First Round
(01 Apr 2015)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2022 | Amount | Post-IPO - Acer Therapeutics | Valuation |
investors |
|
| Jul, 2020 | Amount | Post-IPO - Acer Therapeutics | Valuation |
investors |
|
| Dec, 2017 | Amount | Post-IPO - Acer Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Acer Therapeutics
Acer Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Zevra and TVM Capital Life Science. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Capital is invested in life science innovations for healthcare transformation.
|
Founded Year | Domain | Location | |
|
Marketing services are provided to biopharma companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Acer Therapeutics
Acer Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Opexa Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developing personalized T-cell therapies to treat autoimmune diseases, including multiple sclerosis.
|
2004 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Acer Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acer Therapeutics Comparisons
Competitors of Acer Therapeutics
Acer Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for rare genetic diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acer Therapeutics
Frequently Asked Questions about Acer Therapeutics
When was Acer Therapeutics founded?
Acer Therapeutics was founded in 1991 and raised its 1st funding round 24 years after it was founded.
Where is Acer Therapeutics located?
Acer Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Acer Therapeutics?
Chris Schelling is the current CEO of Acer Therapeutics. They have also founded this company.
How many employees does Acer Therapeutics have?
As of Dec 31, 2022, the latest employee count at Acer Therapeutics is 37.
What is the annual revenue of Acer Therapeutics?
Annual revenue of Acer Therapeutics is $1.26M as on Dec 31, 2021.
What does Acer Therapeutics do?
Acer Therapeutics is developing treatments for ultra-orphan diseases. Its drug portfolio includes ACER-002 for Vascular Ehlers-Danlos Syndrome (vEDS) for which Acer was awarded orphan drug designation by the FDA in January 2015and ACER-001 (orphan drug designation by the FDA in August 2014) for Maple Syrup Urine Disease (MSUD), EDS is a group of hereditary disorders of connective tissue and MSUD is a devastating genetic disease an inborn error of amino acid metabolism. ACER-001 is a reformulation of sodium phenylbutyrate (NaPBA) while Acer is repurposing celiprolol, a unique beta-blocker for the treatment of vEDS.
Who are the top competitors of Acer Therapeutics?
Acer Therapeutics's top competitors include Alnylam, BioMarin Pharmaceutical and Pharvaris.
What products or services does Acer Therapeutics offer?
Acer Therapeutics offers OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities.
How many acquisitions has Acer Therapeutics made?
Acer Therapeutics has made 1 acquisition, including Opexa Therapeutics.
Who are Acer Therapeutics's investors?
Acer Therapeutics has 2 investors. Key investors include Zevra, and TVM Capital Life Science.